Global Bronchial Carcinoid Market, By Types (Central Bronchial Carcinoids, Peripheral Bronchial Carcinoids, Others), Treatment (Surgery, Radiation, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Bronchial Carcinoid Market Analysis and Size
The global bronchial carcinoid market is expected to witness significant growth during the forecast period. Carcinoid tumor is a rare type of malignant disorder that accumulates for less than 1% of all malignant disorders. About 2 to 4 out of 10 carcinoid tumors are found in the lungs. The cause of lung carcinoid tumors is still unknown. Growing cases of carcinoid tumors, mucoepidermoid carcinoma and family history with lung disorders drives the bronchial carcinoid market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global bronchial carcinoid market in the forecast period 2022-2029. The global bronchial carcinoid market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Bronchial Carcinoid Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Central Bronchial Carcinoids, Peripheral Bronchial Carcinoids, Others), Treatment (Surgery, Radiation, Chemotherapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), NATCO Pharma Limited (India), Shilpa Therapeutics Private Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Bronchial carcinoid is uncommon, rare disorder that affects 1 to 2% of all lung cancers in adults. It is a slow growing neuroendocrine tumors and low-grade malignant neoplasms rising from bronchial mucosa. Central bronchial carcinoids are common compared to the peripheral and produces symptoms including bronchial obstruction such as cough, localized wheeze, non-resolving recurrent pneumonitis, chest pain, and fever. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Bronchial Carcinoid Market Dynamics
Drivers
- Increase in Lung Cancer
According to the GLOBOCAN 2020 estimates by the International Agency for Research on Cancer, about 19.3 million new cases of cancer recorded in 2020 and around 11.4% of them were lung cancer. Lung cancer was the primary cause of death with about 18% or 1.8 million global deaths in 2020. Thus this increasing lung cancer result in the origin of bronchial carcinoid and in return this boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global bronchial carcinoid market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Geriatric Population
The elderly population is projected to increase the patient population worldwide, which boots the market in the forecast period. As per the reports of WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The range of possibility of getting infected with varied types of cancer also rises. This boost the market growth.
- Higher Indulgence of Advanced Therapies
The rapid growth of the biopharmaceutical industry and the increasing R&D expenses have resulted in the development of several advanced targeted therapeutics to treat lung cancer. The targeted therapy can efficiently treat cancer cells without altering the body's normal cells. This results in nominal side-effects and removes the chances of reoccurrence and deaths. The rising healthcare expenditure combined with the rising awareness associated with the availability of advanced gene therapies that can cure traditionally non-curable diseases has significantly boosted the growth of the targeted therapy across the globe. This creates more opportunities in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global bronchial carcinoid market over a forecast period.
- High Cost
The huge expenditure of the treatment methods such as radiation therapy, chemotherapy, medications are hamper the market growth.
This global bronchial carcinoid market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global bronchial carcinoid market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Bronchial Carcinoid Market Scope
The global bronchial carcinoid market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Central Bronchial Carcinoids
- Peripheral Bronchial Carcinoids
- Others
Treatment Type
- Surgery
- Radiation Therapy
- Chemotherapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Bronchial Carcinoid Market Regional Analysis/Insights
The global bronchial carcinoid market is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global bronchial carcinoid market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to presence of advanced technology and high R&D & healthcare expenditure.
Asia-Pacific dominates the market due to growing geriatric population suffering from lung disorder, increased usage of cigarettes & alcohol and presence of generic manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bronchial Carcinoid Market Share Analysis
The global bronchial carcinoid market competitive landscape provides details by competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global bronchial carcinoid market.
Key players operating in the global bronchial carcinoid market include:
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- NATCO Pharma Limited (India)
- Shilpa Therapeutics Private Ltd. (India)
SKU-